Allbright assists CF PharmTech, Inc. in completing RMB 630 million E-round financing
2020-01-0211006On January 2, 2020, CF PharmTech, Inc. announced the successful completion of the E-round financing of RMB 630 million. This round of financing is led by New Alliance Capital and co-invested by famous investment institutions such as CR-CP Life, GT Capital, YuanChuang Investment, Cornerstone Capital, Xiangcheng Financial Holding, Everest VC, etc. Existing shareholders such as Yuanhe Holdings, Suzhou Longmen Venture Capital Fund, Gotejia and CMB International Capital also continued to increase their holdings. CEC Capital was the financial advisor of this round of financing.
Founded by a team of scientists and entrepreneurs studying in the United States, CF PharmTech, Inc. is a comprehensive pharmaceutical enterprise dedicated to providing high-quality respiratory system drugs for patients around the world. Since its establishment, the company has been focusing on the development of global respiratory disease treatment drugs. CF PharmTech, Inc. has established advanced inhalation preparation research and development base and production facilities for the global high-end market. At present, the company has applied for more than 20 research projects in China, the United States, Europe and other domestic and foreign markets, including several important drugs for the treatment of respiratory diseases. The success of this round of financing of CF PharmTech, Inc. highlights the full recognition of the important investment institutions of China’s health industry for the intensive work of high-end pharmaceutical enterprises with international competitiveness.
The project team entrusted by CF PharmTech, Inc. includes AllBright Senior Partner Carl Li, Partner Summer Sheng, Senior Associate Levana Wang, Associate Qiongyan Guo, etc. The project team provided legal services for the whole process of financing. Carl Li’s team has rich experience in the field of medical health and life science, and has long provided legal services in investment and financing, M&A and compliance for start-ups, foreign pharmaceutical enterprises, investment funds and innovation incubators in this field.
